2026-09-17T12:45:53.000Z · 12 days ago Mira advances Ketamir-2 to chemotherapy-induced peripheral neuropathy
Sep 17, 2026, 8:30 AM EDT · 12 days ago MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Sep 1, 2026, 8:00 AM EDT · 4 weeks ago MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
2026-08-06T13:38:42.000Z · 7 weeks ago Mira reports positive results in 7-day dog study for obesity candidate SKNY-1
Jul 30, 2026, 8:00 AM EDT · 2 months ago MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Jul 10, 2026, 8:00 AM EDT · 2 months ago MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Jul 6, 2026, 9:00 AM EDT · 2 months ago MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
2026-06-25T12:20:26.000Z · 3 months ago Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55
Jun 25, 2026, 8:15 AM EDT · 3 months ago MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
2026-06-17T12:22:20.000Z · 3 months ago Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2
Jun 17, 2026, 8:00 AM EDT · 3 months ago MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
2026-06-04T12:27:50.000Z · 3 months ago Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1
Jun 4, 2026, 8:00 AM EDT · 3 months ago MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
May 27, 2026, 8:00 AM EDT · 4 months ago MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
2026-05-14T16:26:48.000Z · 4 months ago Mira announces results from Phase 1 trial evaluating Ketamir-2
May 14, 2026, 8:00 AM EDT · 4 months ago MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
May 13, 2026, 8:00 AM EDT · 4 months ago MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
Mar 23, 2026, 9:00 AM EDT · 6 months ago MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Feb 3, 2026, 7:30 AM EST · 7 months ago MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Oct 24, 2025, 7:30 AM EDT · 11 months ago MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Oct 16, 2025, 7:30 AM EDT · 11 months ago MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
Sep 30, 2025, 7:30 AM EDT · 12 months ago MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Sep 22, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Sep 16, 2025, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
Sep 12, 2025, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
Aug 19, 2025, 8:30 AM EDT · 1 year ago MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
Aug 12, 2025, 8:30 AM EDT · 1 year ago MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Jul 30, 2025, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
Jul 29, 2025, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
Jul 11, 2025, 8:00 AM EDT · 1 year ago MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
Jul 3, 2025, 8:00 AM EDT · 1 year ago MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
Jun 30, 2025, 8:00 AM EDT · 1 year ago MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Jun 25, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
Jun 18, 2025, 8:30 AM EDT · 1 year ago MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
May 28, 2025, 8:30 AM EDT · 1 year ago MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
May 8, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
May 6, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
Apr 23, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
Apr 16, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Apr 1, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Mar 24, 2025, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Mar 13, 2025, 8:00 AM EDT · 1 year ago MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Mar 4, 2025, 8:00 AM EST · 1 year ago MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Dec 19, 2024, 9:00 AM EST · 1 year ago MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Dec 10, 2024, 8:30 AM EST · 1 year ago MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Nov 20, 2024, 7:44 AM EST · 1 year ago MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Oct 28, 2024, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Oct 21, 2024, 7:30 AM EDT · 1 year ago MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Sep 27, 2024, 7:30 AM EDT · 2 years ago MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Sep 18, 2024, 7:00 AM EDT · 2 years ago MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
Sep 11, 2024, 7:30 AM EDT · 2 years ago MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Aug 26, 2024, 8:00 AM EDT · 2 years ago MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
Aug 19, 2024, 7:30 AM EDT · 2 years ago MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
Aug 12, 2024, 8:00 AM EDT · 2 years ago MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor